ArticleGastro hep advances2026

Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.

Laurens A van Kleef et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.